Bionano Genomics Inc Stock Price, News & Analysis

Bionano Genomics (BNGO) announced the publication of a study from The First Affiliated Hospital of Zhengzhou, Central China's largest hospital, showcasing the advantages of optical genome mapping (OGM) for structural variant analysis. Conducted by Dr. Xiangdong Kong, the study demonstrated OGM's effectiveness in detecting chromosome balanced translocations compared to traditional methods like karyotype analysis and FISH. This innovative approach could enhance preimplantation genetic testing and address recurrent pregnancy loss, an area of significant unmet need in fertility treatment.

Bionano Genomics reported 80% year-over-year revenue growth in Q1 2022, achieving all ELEVATE! milestones. Total revenue reached $5.7 million, despite a decline in gross margin to 15% from 33% in Q1 2021. The company expanded its Saphyr system installations to 176, a 64% increase year-over-year. With a strong balance sheet of $216.5 million in cash, Bionano remains on track to meet its annual revenue guidance of $24 million to $27 million. The Q1 conference call is scheduled for May 5, 2022, at 4:30 PM ET.

Bionano Genomics (Nasdaq: BNGO) announced a peer-reviewed publication in Nature detailing the NeuroSCORE software, aimed at analyzing complex genetic conditions like autism spectrum disorder (ASD) and epilepsy. This innovative tool identifies over 1,000 genes affecting neurodevelopment, enhancing diagnostics and therapeutic research. The study scored over 18,000 genes based on various data models to prioritize those linked to neurodevelopmental diseases. CEO Erik Holmlin expressed optimism that NeuroSCORE will facilitate the interpretation of unknown genetic variants.

Bionano Genomics (BNGO) has announced a conference call and live webcast to discuss its Q1 2022 financial results on May 5, 2022, at 4:30 p.m. ET. This event aims to highlight the company's recent corporate progress in genome analysis solutions, which support researchers and clinicians in biology and medicine. Bionano's offerings include Optical Genome Mapping (OGM) solutions, diagnostic testing through Lineagen, and BioDiscovery software for genomic data analysis.

TwinStrand Biosciences has appointed Goran Pljevaljcic, Ph.D., as Chief Commercial Officer. He brings over 20 years of experience in the genomics industry, including significant roles at Bionano Genomics (NASDAQ: BNGO). This leadership change aims to strengthen the company's commercial strategy as it expands its high-resolution duplex sequencing offerings, which enhance the detection of low-frequency genomic variants. Dr. Pljevaljcic's expertise is expected to accelerate the deployment of these technologies for clinical applications, improving healthcare outcomes.

Bionano Genomics, Inc. (Nasdaq: BNGO) recently announced the issuance of two new US patents, No. 11,291,999 and No. 11,292,713, by the United States Patent and Trademark Office on April 5, 2022. The ‘999 patent focuses on a novel apparatus for minimizing biopolymer aggregation in nanochannels, enhancing DNA loading cycles. The ‘713 patent expands patent protection for optical genome mapping technology, detailing methods for detecting genomic variants. These patents bolster Bionano's intellectual property portfolio, supporting its goal of advancing genomic insights in clinical research.

Bionano Genomics, Inc. (BNGO), has launched a new integrated genomic scar analysis feature for homologous recombination deficiency (HRD) in its N×Clinical 6.2 software release. This capability allows for a comprehensive, automated analysis of tumor biomarkers from next-generation sequencing and microarray data. It aims to improve therapeutic response stratification across various tumor types. The software can measure genomic instability through three genomic scars, enhancing HRD assessment and supporting clinical trials. Bionano is also collaborating with Friends of Cancer Research on HRD biomarker research.

Bionano Genomics (BNGO) announced a new study showcasing the effectiveness of its optical genome mapping (OGM) technology in characterizing genomic variations in B-cell acute lymphoblastic leukemia (B-ALL). Conducted by University Hospitals Leuven, the study involved 12 subjects and utilized various methods, including OGM and single-cell analysis, to identify genetic variations associated with B-ALL. CEO Erik Holmlin emphasized the growing applications of OGM in cancer research and its potential to complement traditional cytogenetic methods. This advancement underscores OGM's viability as a tool in targeted therapy selection.

Bionano Genomics (BNGO) announces participation in the American Association for Cancer Research (AACR) Annual Meeting from April 8-13, 2022, in New Orleans. The company will showcase its optical genome mapping (OGM) solutions, NxClinical software, and laboratory services. Notable presentations include research on genomic structural variations and homologous recombination deficiency (HRD) analysis. Bionano will also introduce NxClinical version 6.2, enhancing HRD analysis capabilities. This participation aims to demonstrate the potential impact of their solutions in cancer research.